Cargando…
Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors
Diffuse-type gastric carcinomas (DGC) exhibit more aggressive progression and poorer prognosis than intestinal-type and other gastric carcinomas. To identify potential therapeutic targets, we examined protein tyrosine phosphorylation in a panel of DGC and other gastric cancer cell lines. Protein tyr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317844/ https://www.ncbi.nlm.nih.gov/pubmed/24612061 http://dx.doi.org/10.1111/cas.12387 |
_version_ | 1782355741575741440 |
---|---|
author | Yamaguchi, Hideki Takanashi, Miho Yoshida, Nachi Ito, Yuumi Kamata, Reiko Fukami, Kiyoko Yanagihara, Kazuyoshi Sakai, Ryuichi |
author_facet | Yamaguchi, Hideki Takanashi, Miho Yoshida, Nachi Ito, Yuumi Kamata, Reiko Fukami, Kiyoko Yanagihara, Kazuyoshi Sakai, Ryuichi |
author_sort | Yamaguchi, Hideki |
collection | PubMed |
description | Diffuse-type gastric carcinomas (DGC) exhibit more aggressive progression and poorer prognosis than intestinal-type and other gastric carcinomas. To identify potential therapeutic targets, we examined protein tyrosine phosphorylation in a panel of DGC and other gastric cancer cell lines. Protein tyrosine phosphorylation was significantly enhanced or altered in DGC cell lines compared with that in other gastric cancer cell lines. Affinity purification and mass spectrometry analysis of tyrosine-phosphorylated proteins identified Met as a protein that is preferentially expressed and phosphorylated in DGC cell lines. Unexpectedly, Met inhibitors blocked cell growth, Met downstream signaling and peritoneal dissemination in vivo in only a subset of cell lines that exhibited remarkable overexpression of Met. Likewise, only cell lines with overexpression of fibroblast growth factor receptor 2 (FGFR2) or phosphorylation of FRS2 were sensitive to an FGFR2 inhibitor. A Src inhibitor saracatinib impaired growth in cell lines that are insensitive to both Met and FGFR2 inhibitors. Saracatinib also effectively impaired peritoneal dissemination of Met-independent and FGFR2-independent SGC cells. Moreover, DGC cell lines exhibited nearly mutually exclusive susceptibility to Met, FGFR and Src inhibitors. These results suggest that DGC have distinct sensitivities to molecular target drugs and that targeting Src is beneficial in the treatment of DGC insensitive to Met and FGFR inhibition. |
format | Online Article Text |
id | pubmed-4317844 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BlackWell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-43178442015-10-05 Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors Yamaguchi, Hideki Takanashi, Miho Yoshida, Nachi Ito, Yuumi Kamata, Reiko Fukami, Kiyoko Yanagihara, Kazuyoshi Sakai, Ryuichi Cancer Sci Original Articles Diffuse-type gastric carcinomas (DGC) exhibit more aggressive progression and poorer prognosis than intestinal-type and other gastric carcinomas. To identify potential therapeutic targets, we examined protein tyrosine phosphorylation in a panel of DGC and other gastric cancer cell lines. Protein tyrosine phosphorylation was significantly enhanced or altered in DGC cell lines compared with that in other gastric cancer cell lines. Affinity purification and mass spectrometry analysis of tyrosine-phosphorylated proteins identified Met as a protein that is preferentially expressed and phosphorylated in DGC cell lines. Unexpectedly, Met inhibitors blocked cell growth, Met downstream signaling and peritoneal dissemination in vivo in only a subset of cell lines that exhibited remarkable overexpression of Met. Likewise, only cell lines with overexpression of fibroblast growth factor receptor 2 (FGFR2) or phosphorylation of FRS2 were sensitive to an FGFR2 inhibitor. A Src inhibitor saracatinib impaired growth in cell lines that are insensitive to both Met and FGFR2 inhibitors. Saracatinib also effectively impaired peritoneal dissemination of Met-independent and FGFR2-independent SGC cells. Moreover, DGC cell lines exhibited nearly mutually exclusive susceptibility to Met, FGFR and Src inhibitors. These results suggest that DGC have distinct sensitivities to molecular target drugs and that targeting Src is beneficial in the treatment of DGC insensitive to Met and FGFR inhibition. BlackWell Publishing Ltd 2014-05 2014-03-24 /pmc/articles/PMC4317844/ /pubmed/24612061 http://dx.doi.org/10.1111/cas.12387 Text en © 2014 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Yamaguchi, Hideki Takanashi, Miho Yoshida, Nachi Ito, Yuumi Kamata, Reiko Fukami, Kiyoko Yanagihara, Kazuyoshi Sakai, Ryuichi Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors |
title | Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors |
title_full | Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors |
title_fullStr | Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors |
title_full_unstemmed | Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors |
title_short | Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors |
title_sort | saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to met and fibroblast growth factor receptor inhibitors |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4317844/ https://www.ncbi.nlm.nih.gov/pubmed/24612061 http://dx.doi.org/10.1111/cas.12387 |
work_keys_str_mv | AT yamaguchihideki saracatinibimpairstheperitonealdisseminationofdiffusetypegastriccarcinomacellsresistanttometandfibroblastgrowthfactorreceptorinhibitors AT takanashimiho saracatinibimpairstheperitonealdisseminationofdiffusetypegastriccarcinomacellsresistanttometandfibroblastgrowthfactorreceptorinhibitors AT yoshidanachi saracatinibimpairstheperitonealdisseminationofdiffusetypegastriccarcinomacellsresistanttometandfibroblastgrowthfactorreceptorinhibitors AT itoyuumi saracatinibimpairstheperitonealdisseminationofdiffusetypegastriccarcinomacellsresistanttometandfibroblastgrowthfactorreceptorinhibitors AT kamatareiko saracatinibimpairstheperitonealdisseminationofdiffusetypegastriccarcinomacellsresistanttometandfibroblastgrowthfactorreceptorinhibitors AT fukamikiyoko saracatinibimpairstheperitonealdisseminationofdiffusetypegastriccarcinomacellsresistanttometandfibroblastgrowthfactorreceptorinhibitors AT yanagiharakazuyoshi saracatinibimpairstheperitonealdisseminationofdiffusetypegastriccarcinomacellsresistanttometandfibroblastgrowthfactorreceptorinhibitors AT sakairyuichi saracatinibimpairstheperitonealdisseminationofdiffusetypegastriccarcinomacellsresistanttometandfibroblastgrowthfactorreceptorinhibitors |